Healthcare costs and health outcomes analysis of neoadjuvant Trastuzumab therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer
Overall, while adjuvant Trastuzumab remains the most cost-effective strategy for patients with <i>HER2+</i> breast cancer, adopting a neoadjuvant Trastuzumab approach does not appear to pose a significant economic disadvantage. Notably, higher treatment costs were observed among older patients, a finding with important financial implications for healthcare systems. These results highlight the need for careful evaluation to inform forthcoming age-related cancer policy updates.
Authors
- Ciarán O’Neill (ORCID: https://orcid.org/0000-0001-7668-3934)
- James A. L. Brown (ORCID: https://orcid.org/0000-0002-3155-0334)
- Michael J. Kerin (ORCID: https://orcid.org/0000-0003-4164-5561)
- Paddy Gillespie (ORCID: https://orcid.org/0000-0001-6297-9478)
- Shirin Moghaddam (ORCID: https://orcid.org/0000-0002-9965-1510)
- Andrew McGuire (ORCID: https://orcid.org/0000-0002-9474-737X)
- Emer Bourke (ORCID: https://orcid.org/0000-0002-2218-3114)
- Doireann Joyce (ORCID: https://orcid.org/0000-0003-3723-6810)
- Amirhossein Jalali (ORCID: https://orcid.org/0000-0001-7227-8261)
- Bridget Carr
- Diarmuid O’Leary
Institutions
- Ollscoil na Gaillimhe – University of Galway (IE)
- University of Limerick (IE)
- University Hospital Limerick (IE)
- Queens University (BD)
Publication Details
- Journal
- Cancer Pathogenesis and Therapy
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1016/j.cpt.2025.08.006
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00